Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Jolanda HoweSVP, Global Controller | Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 06/17 | 06/18 | 2,594 sh | $101.95 | $264,458.3 | −30.8% |
CFO | Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 06/08 | 06/09 | 5,000 sh3 trades | $93.82avg. | $469,077.01 | −10.0% |
Saira RamasastryDirector | Mirum PharmaceuticalsMIRM | Open-market sale | 06/01 | 06/02 | 3,977 sh | $100.00 | $397,700 | −100.0% |
Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 06/01 | 06/02 | 30,000 sh6 trades | $95.84avg. | $2,875,103.34 | −13.4% | |
Saira RamasastryDirector | Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 05/15 | 05/18 | 2,000 sh | $109.47 | $218,940 | −100.0% |
Saira RamasastryDirector | Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 04/15 | 04/16 | 2,000 sh | $96.90 | $193,800 | −100.0% |
Mirum PharmaceuticalsMIRM | Open-market sale | 03/16 | 03/17 | 7,287 sh | $91.98 | $670,258.26 | −12.8% | |
Saira RamasastryDirector | Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 03/16 | 03/17 | 2,000 sh | $90.76 | $181,520 | −100.0% |
Mirum PharmaceuticalsMIRM | Open-market sale | 03/16 | 03/17 | 40,985 sh | $91.98 | $3,769,800.3 | −17.4% | |
Radovich PeterPresident and COO | Mirum PharmaceuticalsMIRM | Open-market sale | 03/16 | 03/17 | 16,515 sh | $91.98 | $1,519,049.7 | −29.1% |
Joanne QuanChief Medical Officer | Mirum PharmaceuticalsMIRM | Open-market sale | 03/16 | 03/17 | 7,287 sh | $91.98 | $670,258.26 | −27.9% |
Jolanda HoweSVP, Global Controller | Mirum PharmaceuticalsMIRM | Open-market sale | 03/16 | 03/17 | 4,732 sh | $91.98 | $435,249.36 | −36.0% |
Saira RamasastryDirector | Mirum PharmaceuticalsMIRM | Open-market sale10b5-1 plan | 02/13 | 02/17 | 2,000 sh | $102.09 | $204,180 | −100.0% |
Mirum PharmaceuticalsMIRM | Open-market sale | 02/02 | 02/03 | 9,108 sh | $103.30 | $940,856.4 | −5.4% | |
Radovich PeterPresident and COO | Mirum PharmaceuticalsMIRM | Open-market sale | 02/02 | 02/03 | 2,631 sh | $103.30 | $271,782.3 | −11.3% |
Jolanda HoweSVP, Global Controller | Mirum PharmaceuticalsMIRM | Open-market sale | 02/02 | 02/03 | 968 sh | $103.30 | $99,994.4 | −17.7% |
Mirum PharmaceuticalsMIRM | Open-market sale | 01/26 | 01/27 | 1,053 sh | $96.19 | $101,288.07 | −2.4% | |
Mirum PharmaceuticalsMIRM | Open-market sale | 01/26 | 01/27 | 6,831 sh | $96.19 | $657,073.89 | −3.9% | |
Radovich PeterPresident and COO | Mirum PharmaceuticalsMIRM | Open-market sale | 01/26 | 01/27 | 3,143 sh | $96.19 | $302,325.17 | −11.9% |
Jolanda HoweSVP, Global Controller | Mirum PharmaceuticalsMIRM | Open-market sale | 01/26 | 01/27 | 842 sh | $96.19 | $80,991.98 | −18.5% |
